Hutchison MediPharma Ltd.(HMPL) was founded in September 2002. It is the R&D subsidiary of Hutchison China MediTech Ltd, a company on United Kingdom stock market (AIM: HCM). HMPL has a fully integrated drug discovery and development infrastructure, cutting-edge drug platforms, and an experienced senior management team drawn largely from
leading pharmaceutical and biotechnology companies. Over a short period of time, the company has established an emerging portfolio of preclinical and clinical candidates in oncology and anti-autoimmune/inflammatory diseases. HMPL-002, a radiosensitizer is currently in the US phase I/II trials in combination with radiotherapy and chemotherapy for the treatment of head and neck cancer. HMPL-004, a proinflammatory cytokine inhibitor, is in the US phase II trials for the treatment of inflammatory bowel disease. Several preclinical and clinical studies are also ongoing in China.
HMPL combines world-class R&D expertise and technologies with Chinese resources to produce clinical candidates with high quality and reach human proof of concept more rapidly. HMPL takes a tripartite discovery approach for optimal productivity, including botanical drugs, natural-product semi-synthesis, and synthetic small molecules.
HMPL is an entrepreneurial biotechnology company fully supported by our parent company, Hutchison Whampoa Limited (HWL). HWL was established in Hong Kong in the 19th century, and is one of the Fortune 500 companies with diversified business interests in a global setting.
Address: 13th floor, Huasheng Mansion, No. 399 Jiujiang Road, Huangpu Dist. Shanghai China
Zip Code: 200001
Tel: 86-21-63503300
Fax: 86-21-63506263
The 10th Shanghai International Forum on Biotechnology and Pharmacy
